Biotech News

Vistagen Reports Fiscal Year 2027 Second Quarter Financial Results and Provides Corporate Update

Vistagen Therapeutics, Inc. (VTGN)Vistagen Therapeutics, Inc.Earnings

Advancing potential to execute Phase 3 development plan for fasedienol in social anxiety disorder following constructive FDA feedback, with disciplined capital management and strategic flexibility Advancing potential to execute Phase 3 development plan for fasedienol in social anxiety disorder following constructive FDA feedback, with disciplined capital management and strategic flexibility

Related news

Vistagen Therapeutics, Inc.

Intranasal Pherine Platform Vistagen is a late clinical-stage biopharmaceutical company developing rapid-onset intranasal therapies that modulate nose-to-brain neurocircuitry. Its pherine candidates are designed to produce therapeutic effects without requiring systemic absorption or direct uptake into the brain, potentially reducing...

Recent company news

Stock data

Close
0.19 USD
Market cap
22.98M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States